25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BMRN (Biomarin) Stock Analysis
Buy, Hold or Sell?

Let's analyze Biomarin together

I guess you are interested in Biomarin Pharmaceutical Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Biomarin’s Financial Insights
  • 📈 Technical Analysis (TA) – Biomarin’s Price Targets

I'm going to help you getting a better view of Biomarin Pharmaceutical Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Biomarin Pharmaceutical Inc

I send you an email if I find something interesting about Biomarin Pharmaceutical Inc.

1. Quick Overview

1.1. Quick analysis of Biomarin (30 sec.)










1.2. What can you expect buying and holding a share of Biomarin? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$29.49
Expected worth in 1 year
$33.51
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
$4.02
Return On Investment
7.0%

For what price can you sell your share?

Current Price per Share
$57.50
Expected price per share
$52.93 - $68.42
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Biomarin (5 min.)




Live pricePrice per Share (EOD)
$57.50
Intrinsic Value Per Share
$23.47 - $78.74
Total Value Per Share
$52.96 - $108.23

2.2. Growth of Biomarin (5 min.)




Is Biomarin growing?

Current yearPrevious yearGrowGrow %
How rich?$5.7b$4.9b$611.5m11.0%

How much money is Biomarin making?

Current yearPrevious yearGrowGrow %
Making money$130.9m$51.3m$79.6m60.8%
Net Profit Margin17.8%8.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Biomarin (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#18 / 881

Most Revenue
#22 / 881

Most Profit
#19 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Biomarin?

Welcome investor! Biomarin's management wants to use your money to grow the business. In return you get a share of Biomarin.

First you should know what it really means to hold a share of Biomarin. And how you can make/lose money.

Speculation

The Price per Share of Biomarin is $57.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biomarin.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biomarin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $29.49. Based on the TTM, the Book Value Change Per Share is $1.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.37 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biomarin.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.951.6%0.661.2%0.260.5%0.340.6%0.410.7%0.090.2%
Usd Book Value Change Per Share0.711.2%1.011.7%0.370.6%0.581.0%0.631.1%0.420.7%
Usd Dividend Per Share0.000.0%0.000.0%0.030.0%0.040.1%0.030.0%0.010.0%
Usd Total Gains Per Share0.711.2%1.011.7%0.400.7%0.621.1%0.661.1%0.430.8%
Usd Price Per Share70.69-72.26-89.73-84.69-85.26-87.92-
Price to Earnings Ratio18.70-28.93-114.12--1,644.07--968.12--552.52-
Price-to-Total Gains Ratio100.24-76.37-79.67-142.20--16.71--105.22-
Price to Book Ratio2.40-2.59-3.54-3.33-3.66-5.07-
Price-to-Total Gains Ratio100.24-76.37-79.67-142.20--16.71--105.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share57.5
Number of shares17
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share1.010.63
Usd Total Gains Per Share1.010.66
Gains per Quarter (17 shares)17.1011.15
Gains per Year (17 shares)68.4144.61
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10685824335
2013712648680
302051945128125
402742627171170
503423309214215
6041039811257260
7047946613300305
8054753414343350
9061660216385395
10068467018428440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%15.05.00.075.0%19.021.00.047.5%30.075.00.028.6%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%30.010.00.075.0%69.036.00.065.7%
Dividend per Share0.00.04.00.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%5.00.0100.04.8%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%31.09.00.077.5%70.035.00.066.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Biomarin Pharmaceutical Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7051.006-30%0.373+89%0.580+22%0.630+12%0.421+68%
Book Value Per Share--29.48728.023+5%25.334+16%25.726+15%23.919+23%19.099+54%
Current Ratio--5.5204.543+22%8.835-38%6.125-10%5.447+1%4.388+26%
Debt To Asset Ratio--0.1890.210-10%0.271-30%0.251-25%0.273-31%0.310-39%
Debt To Equity Ratio--0.2340.268-13%0.372-37%0.338-31%0.381-39%0.458-49%
Dividend Per Share----0%0.027-100%0.044-100%0.026-100%0.013-100%
Enterprise Value--13807534060.00013959193117.500-1%16714500290.000-17%15961239302.500-13%15965183613.500-14%16388315085.750-16%
Eps--0.9450.663+42%0.262+260%0.339+178%0.415+128%0.094+909%
Ev To Ebitda Ratio--15.41819.399-21%53.210-71%84.248-82%10.011+54%41.932-63%
Ev To Sales Ratio--4.6324.761-3%6.758-31%6.485-29%7.360-37%10.325-55%
Free Cash Flow Per Share--0.8020.786+2%0.211+280%0.342+134%0.235+241%-0.032+104%
Free Cash Flow To Equity Per Share--0.6050.123+393%0.186+225%0.098+515%0.135+348%0.017+3418%
Gross Profit Margin--1.0000.206+386%-1.905+290%42.339-98%25.276-96%13.304-92%
Intrinsic Value_10Y_max--78.743----------
Intrinsic Value_10Y_min--23.471----------
Intrinsic Value_1Y_max--2.316----------
Intrinsic Value_1Y_min--0.294----------
Intrinsic Value_3Y_max--11.208----------
Intrinsic Value_3Y_min--2.672----------
Intrinsic Value_5Y_max--25.221----------
Intrinsic Value_5Y_min--6.990----------
Market Cap11027120000.000-26%13888747060.00014293763867.500-3%17442832540.000-20%16486872552.500-16%16531314013.500-16%16951479710.750-18%
Net Profit Margin--0.2490.178+40%0.083+201%0.097+156%0.144+74%-0.007+103%
Operating Margin--0.3160.231+37%0.103+208%0.124+154%0.067+373%-0.039+112%
Operating Ratio--0.7000.799-12%0.929-25%0.899-22%0.962-27%1.052-34%
Pb Ratio1.950-23%2.3972.591-7%3.541-32%3.332-28%3.661-35%5.071-53%
Pe Ratio15.210-23%18.69928.930-35%114.123-84%-1644.069+8892%-968.125+5277%-552.520+3055%
Price Per Share57.500-23%70.69072.260-2%89.730-21%84.694-17%85.257-17%87.920-20%
Price To Free Cash Flow Ratio17.918-23%22.02825.360-13%-9.177+142%1.948+1031%-52.146+337%-139.199+732%
Price To Total Gains Ratio81.540-23%100.24576.367+31%79.671+26%142.201-30%-16.711+117%-105.220+205%
Quick Ratio--3.5582.904+23%6.143-42%4.391-19%4.116-14%3.624-2%
Return On Assets--0.0260.019+39%0.008+242%0.010+168%0.013+107%0.000+100%
Return On Equity--0.0320.024+36%0.010+209%0.013+155%0.018+81%-0.001+104%
Total Gains Per Share--0.7051.006-30%0.400+76%0.624+13%0.656+7%0.434+62%
Usd Book Value--5793459000.0005537786000.000+5%4926272250.000+18%5015979416.667+16%4646005600.000+25%3692166575.000+57%
Usd Book Value Change Per Share--0.7051.006-30%0.373+89%0.580+22%0.630+12%0.421+68%
Usd Book Value Per Share--29.48728.023+5%25.334+16%25.726+15%23.919+23%19.099+54%
Usd Dividend Per Share----0%0.027-100%0.044-100%0.026-100%0.013-100%
Usd Enterprise Value--13807534060.00013959193117.500-1%16714500290.000-17%15961239302.500-13%15965183613.500-14%16388315085.750-16%
Usd Eps--0.9450.663+42%0.262+260%0.339+178%0.415+128%0.094+909%
Usd Free Cash Flow--157626000.000155045500.000+2%40803250.000+286%67097083.333+135%46071350.000+242%-5730800.000+104%
Usd Free Cash Flow Per Share--0.8020.786+2%0.211+280%0.342+134%0.235+241%-0.032+104%
Usd Free Cash Flow To Equity Per Share--0.6050.123+393%0.186+225%0.098+515%0.135+348%0.017+3418%
Usd Market Cap11027120000.000-26%13888747060.00014293763867.500-3%17442832540.000-20%16486872552.500-16%16531314013.500-16%16951479710.750-18%
Usd Price Per Share57.500-23%70.69072.260-2%89.730-21%84.694-17%85.257-17%87.920-20%
Usd Profit--185686000.000130970750.000+42%51363750.000+262%66746083.333+178%81769500.000+127%18803825.000+887%
Usd Revenue--745145000.000734441250.000+1%618900750.000+20%631916083.333+18%565350650.000+32%453055125.000+64%
Usd Total Gains Per Share--0.7051.006-30%0.400+76%0.624+13%0.656+7%0.434+62%
 EOD+4 -4MRQTTM+27 -11YOY+28 -123Y+25 -155Y+28 -1210Y+27 -13

3.3 Fundamental Score

Let's check the fundamental score of Biomarin Pharmaceutical Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.210
Price to Book Ratio (EOD)Between0-11.950
Net Profit Margin (MRQ)Greater than00.249
Operating Margin (MRQ)Greater than00.316
Quick Ratio (MRQ)Greater than13.558
Current Ratio (MRQ)Greater than15.520
Debt to Asset Ratio (MRQ)Less than10.189
Debt to Equity Ratio (MRQ)Less than10.234
Return on Equity (MRQ)Greater than0.150.032
Return on Assets (MRQ)Greater than0.050.026
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Biomarin Pharmaceutical Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.644
Ma 20Greater thanMa 5055.822
Ma 50Greater thanMa 10058.247
Ma 100Greater thanMa 20062.571
OpenGreater thanClose57.460
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Fundamental data was last updated by Penke on 2025-06-19 01:19:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Biomarin earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • A Net Profit Margin of 24.9% means that $0.25 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 24.9%. The company is making a huge profit. +2
  • The TTM is 17.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ24.9%TTM17.8%+7.1%
TTM17.8%YOY8.3%+9.5%
TTM17.8%5Y14.4%+3.4%
5Y14.4%10Y-0.7%+15.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.9%-91.7%+116.6%
TTM17.8%-139.0%+156.8%
YOY8.3%-194.4%+202.7%
3Y9.7%-248.5%+258.2%
5Y14.4%-343.3%+357.7%
10Y-0.7%-488.9%+488.2%
4.3.1.2. Return on Assets

Shows how efficient Biomarin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • 2.6% Return on Assets means that Biomarin generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 2.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.6%TTM1.9%+0.7%
TTM1.9%YOY0.8%+1.1%
TTM1.9%5Y1.3%+0.6%
5Y1.3%10Y0.0%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6%-11.6%+14.2%
TTM1.9%-11.7%+13.6%
YOY0.8%-11.4%+12.2%
3Y1.0%-11.9%+12.9%
5Y1.3%-12.0%+13.3%
10Y0.0%-13.8%+13.8%
4.3.1.3. Return on Equity

Shows how efficient Biomarin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • 3.2% Return on Equity means Biomarin generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 3.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.2%TTM2.4%+0.9%
TTM2.4%YOY1.0%+1.3%
TTM2.4%5Y1.8%+0.6%
5Y1.8%10Y-0.1%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2%-13.5%+16.7%
TTM2.4%-15.0%+17.4%
YOY1.0%-14.5%+15.5%
3Y1.3%-16.9%+18.2%
5Y1.8%-17.7%+19.5%
10Y-0.1%-19.9%+19.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Biomarin Pharmaceutical Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Biomarin is operating .

  • Measures how much profit Biomarin makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • An Operating Margin of 31.6% means the company generated $0.32  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 31.6%. The company is operating very efficient. +2
  • The TTM is 23.1%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ31.6%TTM23.1%+8.4%
TTM23.1%YOY10.3%+12.9%
TTM23.1%5Y6.7%+16.4%
5Y6.7%10Y-3.9%+10.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.6%-232.5%+264.1%
TTM23.1%-250.3%+273.4%
YOY10.3%-208.4%+218.7%
3Y12.4%-221.7%+234.1%
5Y6.7%-344.1%+350.8%
10Y-3.9%-470.4%+466.5%
4.3.2.2. Operating Ratio

Measures how efficient Biomarin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.70 means that the operating costs are $0.70 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 0.700. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.799. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.700TTM0.799-0.099
TTM0.799YOY0.929-0.131
TTM0.7995Y0.962-0.164
5Y0.96210Y1.052-0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7002.108-1.408
TTM0.7992.680-1.881
YOY0.9293.080-2.151
3Y0.8993.621-2.722
5Y0.9624.734-3.772
10Y1.0526.546-5.494
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Biomarin Pharmaceutical Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Biomarin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.52 means the company has $5.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 5.520. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.543. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.520TTM4.543+0.978
TTM4.543YOY8.835-4.292
TTM4.5435Y5.447-0.904
5Y5.44710Y4.388+1.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5203.616+1.904
TTM4.5433.826+0.717
YOY8.8354.141+4.694
3Y6.1254.661+1.464
5Y5.4475.756-0.309
10Y4.3886.149-1.761
4.4.3.2. Quick Ratio

Measures if Biomarin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • A Quick Ratio of 3.56 means the company can pay off $3.56 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 3.558. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.904. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.558TTM2.904+0.654
TTM2.904YOY6.143-3.239
TTM2.9045Y4.116-1.212
5Y4.11610Y3.624+0.492
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5582.799+0.759
TTM2.9043.143-0.239
YOY6.1433.794+2.349
3Y4.3914.307+0.084
5Y4.1165.707-1.591
10Y3.6246.457-2.833
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Biomarin Pharmaceutical Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Biomarin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biomarin to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Biomarin assets are financed with 18.9% credit (debt) and the remaining percentage (100% - 18.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 0.189. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.210. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.189TTM0.210-0.021
TTM0.210YOY0.271-0.061
TTM0.2105Y0.273-0.063
5Y0.27310Y0.310-0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1890.327-0.138
TTM0.2100.348-0.138
YOY0.2710.327-0.056
3Y0.2510.340-0.089
5Y0.2730.349-0.076
10Y0.3100.379-0.069
4.5.4.2. Debt to Equity Ratio

Measures if Biomarin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biomarin to the Biotechnology industry mean.
  • A Debt to Equity ratio of 23.4% means that company has $0.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biomarin Pharmaceutical Inc:

  • The MRQ is 0.234. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.268. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.234TTM0.268-0.034
TTM0.268YOY0.372-0.104
TTM0.2685Y0.381-0.113
5Y0.38110Y0.458-0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2340.379-0.145
TTM0.2680.435-0.167
YOY0.3720.412-0.040
3Y0.3380.448-0.110
5Y0.3810.460-0.079
10Y0.4580.509-0.051
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biomarin generates.

  • Above 15 is considered overpriced but always compare Biomarin to the Biotechnology industry mean.
  • A PE ratio of 18.70 means the investor is paying $18.70 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biomarin Pharmaceutical Inc:

  • The EOD is 15.210. Based on the earnings, the company is fair priced.
  • The MRQ is 18.699. Based on the earnings, the company is fair priced.
  • The TTM is 28.930. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD15.210MRQ18.699-3.489
MRQ18.699TTM28.930-10.230
TTM28.930YOY114.123-85.194
TTM28.9305Y-968.125+997.054
5Y-968.12510Y-552.520-415.605
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.210-2.303+17.513
MRQ18.699-2.062+20.761
TTM28.930-2.541+31.471
YOY114.123-3.741+117.864
3Y-1,644.069-3.754-1,640.315
5Y-968.125-6.136-961.989
10Y-552.520-6.686-545.834
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biomarin Pharmaceutical Inc:

  • The EOD is 17.918. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 22.028. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 25.360. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD17.918MRQ22.028-4.110
MRQ22.028TTM25.360-3.332
TTM25.360YOY-9.177+34.538
TTM25.3605Y-52.146+77.507
5Y-52.14610Y-139.199+87.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.918-3.178+21.096
MRQ22.028-2.700+24.728
TTM25.360-3.619+28.979
YOY-9.177-4.357-4.820
3Y1.948-5.065+7.013
5Y-52.146-8.478-43.668
10Y-139.199-9.275-129.924
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Biomarin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.40 means the investor is paying $2.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Biomarin Pharmaceutical Inc:

  • The EOD is 1.950. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.397. Based on the equity, the company is underpriced. +1
  • The TTM is 2.591. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.950MRQ2.397-0.447
MRQ2.397TTM2.591-0.194
TTM2.591YOY3.541-0.950
TTM2.5915Y3.661-1.070
5Y3.66110Y5.071-1.410
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9501.963-0.013
MRQ2.3971.848+0.549
TTM2.5912.119+0.472
YOY3.5412.469+1.072
3Y3.3322.526+0.806
5Y3.6613.664-0.003
10Y5.0714.351+0.720
4.6.2. Total Gains per Share

2.4. Latest News of Biomarin Pharmaceutical Inc

Does Biomarin Pharmaceutical Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Biomarin Pharmaceutical Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-28
10:16
BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia ARead
2025-06-23
07:38
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy RatingRead
2025-06-20
23:00
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersRead
2025-06-19
06:37
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice AboutRead
2025-06-15
11:26
Jim Cramer on BioMarin: “I Don’t Think It Works Now”Read
2025-06-14
07:49
BioMarin's SWOT analysis: stock growth potential amid rare disease focusRead
2025-06-09
15:45
Are You a Growth Investor? This 1 Stock Could Be the Perfect PickRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Biomarin Pharmaceutical Inc.

4.8.1. Institutions holding Biomarin Pharmaceutical Inc

Institutions are holding 98.973% of the shares of Biomarin Pharmaceutical Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc12.39940.0353237789992658831.1308
2025-03-31Vanguard Group Inc9.90910.024319003212-368973-1.9047
2025-03-31PRIMECAP Management Company9.26771.038717773281-415890-2.2865
2025-03-31Dodge & Cox7.79830.6026149552402090051.4173
2025-03-31Viking Global Investors LP5.63162.4255108000592895092.7545
2025-03-31Capital Research Global Investors4.77150.14079150655-3841117-29.5658
2025-03-31State Street Corp4.4130.02478463090-649185-7.1243
2025-03-31Ameriprise Financial Inc2.1940.08034207563-292685-6.5038
2024-12-31NORGES BANK1.86150.03083569831-49672-1.3723
2025-03-31Elliott Investment Management LP1.82521.6326350033800
2025-03-31Geode Capital Management, LLC1.78920.01934312531424754.3322
2025-03-31AQR Capital Management LLC1.52560.210129258051642206127.9376
2025-03-31Nuveen, LLC1.36080.0142260963926096390
2025-03-31Deutsche Bank AG0.98410.0529188735321783513.0478
2025-03-31Northern Trust Corp0.88480.01781696864-28175-1.6333
2025-03-31Citadel Advisors Llc0.83170.021415950581207445311.5079
2025-03-31Goldman Sachs Group Inc0.83060.018215929631083512212.6823
2025-03-31Charles Schwab Investment Management Inc0.7990.020315323141088067.6435
2024-12-31UBS Group AG0.78670.0183150863364666275.0213
2025-03-31Squarepoint Ops LLC0.72410.11921388728695590100.3538
Total 70.58796.5469135370878+3472870+2.6%

4.9.2. Funds holding Biomarin Pharmaceutical Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Dodge & Cox Stock I5.09430.6094976962500
2025-03-31Capital Group Growth Fnd of Amer Comp4.31720.212782794087415649.8379
2025-03-31American Funds Growth Fund of Amer A4.31720.212782794087415649.8379
2025-03-31Vanguard PRIMECAP Inv3.69690.69977089768-75320-1.0512
2025-05-31iShares Core S&P Mid-Cap ETF3.2270.3915618863600
2025-04-30Vanguard Total Stock Mkt Idx Inv3.19540.02276128040971261.6105
2025-03-31Vanguard Capital Opportunity Inv2.86921.8245502350-7520-0.1365
2025-04-30Vanguard Small Cap Index2.49740.21744789456279080.5861
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.53750.18432948550149880.5109
2025-04-30Vanguard Small Cap Growth Index Inv1.39030.50852666314-3282-0.1229
2025-03-31PRIMECAP Odyssey Aggressive Growth0.93292.13321789110-73490-3.9456
2025-05-31SPDR® S&P Biotech ETF0.78571.8648150674989180.5954
2025-04-30SPDR® S&P MIDCAP 400 ETF Trust0.78470.45491504951-16740-1.1001
2025-04-30R-co Valor C EUR0.7131.2121367373898687.0346
2025-03-31Columbia Contrarian Large Cap Core0.69120.68271325639-97820-6.872
2025-04-30Columbia Contrarian Core Inst0.69120.621132563900
2025-03-31PRIMECAP Odyssey Growth0.62791.81371204066-150830-11.1322
2025-05-31iShares Biotechnology ETF0.58091.2957111399900
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.57970.15691111683195001.7854
2025-05-31iShares S&P Mid-Cap 400 Value ETF0.55340.8221106135100
Total 39.08315.939974952115+1316434+1.8%

5.3. Insider Transactions

Insiders are holding 0.85% of the shares of Biomarin Pharmaceutical Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-20Erin BurkhartSELL178659.31
2025-05-02Cristin HubbardSELL27364.92
2025-03-19Erin BurkhartSELL129571.52
2025-02-24Erin BurkhartSELL134468.38
2024-11-12Charles Greg GuyerSELL527866.37
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Depreciation and Amortization  27,350-88726,463-7,45719,0064,60123,607-34,940-11,333



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,147,007
Total Liabilities1,353,548
Total Stockholder Equity5,793,459
 As reported
Total Liabilities 1,353,548
Total Stockholder Equity+ 5,793,459
Total Assets = 7,147,007

Assets

Total Assets7,147,007
Total Current Assets3,467,905
Long-term Assets3,679,102
Total Current Assets
Cash And Cash Equivalents 1,048,803
Short-term Investments 223,532
Net Receivables 739,177
Inventory 1,274,848
Other Current Assets 181,545
Total Current Assets  (as reported)3,467,905
Total Current Assets  (calculated)3,467,905
+/-0
Long-term Assets
Property Plant Equipment 1,032,613
Goodwill 196,199
Long Term Investments 506,724
Intangible Assets 247,346
Long-term Assets Other 235,654
Long-term Assets  (as reported)3,679,102
Long-term Assets  (calculated)2,218,536
+/- 1,460,566

Liabilities & Shareholders' Equity

Total Current Liabilities628,213
Long-term Liabilities725,335
Total Stockholder Equity5,793,459
Total Current Liabilities
Accounts payable 293,751
Other Current Liabilities 628,213
Total Current Liabilities  (as reported)628,213
Total Current Liabilities  (calculated)921,964
+/- 293,751
Long-term Liabilities
Long term Debt 595,650
Capital Lease Obligations Min Short Term Debt6,309
Long-term Liabilities Other 129,685
Long-term Liabilities  (as reported)725,335
Long-term Liabilities  (calculated)731,644
+/- 6,309
Total Stockholder Equity
Retained Earnings -9,009
Accumulated Other Comprehensive Income 19,151
Other Stockholders Equity 5,783,317
Total Stockholder Equity (as reported)5,793,459
Total Stockholder Equity (calculated)5,793,459
+/-0
Other
Capital Stock192
Cash and Short Term Investments 1,272,335
Common Stock Shares Outstanding 196,474
Liabilities and Stockholders Equity 7,147,007
Net Debt -453,153
Net Invested Capital 6,389,109
Net Working Capital 2,839,692
Property Plant and Equipment Gross 1,940,801
Short Long Term Debt Total 595,650



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-31
> Total Assets 
26,800
51,400
112,500
103,549
94,490
86,090
83,324
76,933
65,443
98,321
90,402
171,811
157,306
141,973
127,469
110,616
183,117
306,385
284,446
256,340
239,296
347,416
312,230
232,966
180,933
167,247
208,842
195,303
488,229
468,714
467,072
463,436
449,764
781,639
791,056
815,279
827,702
854,555
859,038
906,695
900,283
844,437
869,357
917,163
966,205
985,516
1,244,533
1,262,623
1,264,146
1,280,392
1,295,076
1,303,681
1,297,085
1,532,527
1,567,376
1,601,643
1,598,293
1,601,520
1,620,530
2,249,217
2,340,728
2,345,685
2,440,433
2,490,453
3,658,686
3,648,689
3,624,853
3,729,368
3,666,993
3,087,304
3,842,238
4,023,690
3,938,607
4,019,965
4,580,697
4,633,125
4,596,717
4,624,679
4,695,254
4,427,128
4,435,398
4,393,384
4,558,128
4,690,039
4,722,841
5,302,110
6,158,090
5,848,020
5,805,053
5,898,496
5,977,475
6,003,325
6,062,707
6,145,841
6,264,040
6,375,074
6,433,695
6,563,172
6,758,163
6,841,603
6,872,673
7,067,121
6,851,195
6,988,940
7,147,007
7,147,0076,988,9406,851,1957,067,1216,872,6736,841,6036,758,1636,563,1726,433,6956,375,0746,264,0406,145,8416,062,7076,003,3255,977,4755,898,4965,805,0535,848,0206,158,0905,302,1104,722,8414,690,0394,558,1284,393,3844,435,3984,427,1284,695,2544,624,6794,596,7174,633,1254,580,6974,019,9653,938,6074,023,6903,842,2383,087,3043,666,9933,729,3683,624,8533,648,6893,658,6862,490,4532,440,4332,345,6852,340,7282,249,2171,620,5301,601,5201,598,2931,601,6431,567,3761,532,5271,297,0851,303,6811,295,0761,280,3921,264,1461,262,6231,244,533985,516966,205917,163869,357844,437900,283906,695859,038854,555827,702815,279791,056781,639449,764463,436467,072468,714488,229195,303208,842167,247180,933232,966312,230347,416239,296256,340284,446306,385183,117110,616127,469141,973157,306171,81190,40298,32165,44376,93383,32486,09094,490103,549112,50051,40026,800
   > Total Current Assets 
5,500
21,100
76,400
66,422
61,552
53,532
51,414
44,541
35,861
63,586
50,642
136,783
123,426
105,555
91,370
81,072
154,795
275,052
254,206
225,269
208,825
181,587
140,687
85,277
53,599
39,336
82,188
68,941
378,759
344,807
339,366
334,224
320,645
640,932
641,234
644,297
683,728
701,814
697,013
737,696
713,575
506,981
520,267
467,727
500,431
521,908
554,189
504,260
503,830
514,111
487,024
469,802
513,390
681,534
719,386
743,462
723,024
720,920
713,479
1,137,418
1,246,410
1,220,227
1,077,819
1,425,629
1,522,728
1,213,929
1,175,589
1,089,639
992,790
1,105,946
1,666,571
1,421,791
1,352,788
1,458,820
2,050,029
2,207,144
2,241,110
2,280,067
2,407,853
2,056,215
1,916,855
1,806,768
1,859,359
1,942,143
2,116,249
2,647,566
2,738,979
2,342,219
2,288,766
2,357,837
2,311,570
2,274,385
2,394,024
2,517,598
2,682,701
2,751,457
2,842,105
2,950,117
2,955,308
2,956,088
2,985,012
3,259,630
3,056,590
3,232,427
3,467,905
3,467,9053,232,4273,056,5903,259,6302,985,0122,956,0882,955,3082,950,1172,842,1052,751,4572,682,7012,517,5982,394,0242,274,3852,311,5702,357,8372,288,7662,342,2192,738,9792,647,5662,116,2491,942,1431,859,3591,806,7681,916,8552,056,2152,407,8532,280,0672,241,1102,207,1442,050,0291,458,8201,352,7881,421,7911,666,5711,105,946992,7901,089,6391,175,5891,213,9291,522,7281,425,6291,077,8191,220,2271,246,4101,137,418713,479720,920723,024743,462719,386681,534513,390469,802487,024514,111503,830504,260554,189521,908500,431467,727520,267506,981713,575737,696697,013701,814683,728644,297641,234640,932320,645334,224339,366344,807378,75968,94182,18839,33653,59985,277140,687181,587208,825225,269254,206275,052154,79581,07291,370105,555123,426136,78350,64263,58635,86144,54151,41453,53261,55266,42276,40021,1005,500
       Cash And Cash Equivalents 
3,600
17,200
32,600
23,413
40,675
10,609
16,098
16,530
19,722
18,967
7,230
12,528
18,202
19,363
32,405
33,638
125,835
221,772
187,978
121,406
96,199
48,247
34,981
13,081
11,246
17,111
56,213
38,092
341,689
285,990
191,782
89,162
98,331
205,010
291,825
228,343
319,990
252,209
271,217
222,900
214,579
200,050
191,778
167,171
108,963
115,779
127,539
88,079
90,782
112,956
71,254
46,272
82,586
177,757
181,330
180,527
154,380
175,445
181,565
568,781
639,778
584,717
398,005
875,486
900,570
440,664
376,346
397,040
270,453
305,969
707,349
408,330
348,234
354,864
431,399
598,028
473,980
427,411
882,184
493,982
364,369
307,577
423,220
437,446
476,632
818,900
1,015,675
649,158
667,313
641,533
617,143
587,276
605,440
619,802
761,515
724,531
580,074
694,381
785,414
755,127
746,996
972,150
675,448
942,842
1,048,803
1,048,803942,842675,448972,150746,996755,127785,414694,381580,074724,531761,515619,802605,440587,276617,143641,533667,313649,1581,015,675818,900476,632437,446423,220307,577364,369493,982882,184427,411473,980598,028431,399354,864348,234408,330707,349305,969270,453397,040376,346440,664900,570875,486398,005584,717639,778568,781181,565175,445154,380180,527181,330177,75782,58646,27271,254112,95690,78288,079127,539115,779108,963167,171191,778200,050214,579222,900271,217252,209319,990228,343291,825205,01098,33189,162191,782285,990341,68938,09256,21317,11111,24613,08134,98148,24796,199121,406187,978221,772125,83533,63832,40519,36318,20212,5287,23018,96719,72216,53016,09810,60940,67523,41332,60017,2003,600
       Short-term Investments 
300
300
39,600
39,573
14,999
38,803
31,407
23,671
10,044
40,918
36,675
118,569
96,596
81,195
54,063
40,340
22,743
44,588
53,911
84,951
94,999
80,549
51,570
35,734
18,513
9,574
9,700
9,700
6,000
19,910
102,118
199,685
174,976
382,700
294,861
357,251
254,772
323,448
291,752
336,892
337,290
146,341
171,566
133,506
214,679
221,894
224,428
186,033
161,799
145,964
153,120
148,820
150,393
224,829
245,125
270,211
247,502
225,116
198,086
215,942
247,703
251,901
268,368
69,706
108,119
240,889
241,984
195,579
186,400
197,318
327,499
381,347
329,821
372,912
825,700
797,940
908,815
935,662
561,192
590,326
530,485
423,526
297,572
316,361
381,764
561,472
489,998
416,228
420,178
481,864
462,333
426,599
450,798
489,945
512,253
567,006
572,017
476,577
340,431
318,683
299,584
252,201
254,996
194,864
223,532
223,532194,864254,996252,201299,584318,683340,431476,577572,017567,006512,253489,945450,798426,599462,333481,864420,178416,228489,998561,472381,764316,361297,572423,526530,485590,326561,192935,662908,815797,940825,700372,912329,821381,347327,499197,318186,400195,579241,984240,889108,11969,706268,368251,901247,703215,942198,086225,116247,502270,211245,125224,829150,393148,820153,120145,964161,799186,033224,428221,894214,679133,506171,566146,341337,290336,892291,752323,448254,772357,251294,861382,700174,976199,685102,11819,9106,0009,7009,7009,57418,51335,73451,57080,54994,99984,95153,91144,58822,74340,34054,06381,19596,596118,56936,67540,91810,04423,67131,40738,80314,99939,57339,600300300
       Net Receivables 
900
1,500
400
2,466
5,006
3,018
2,960
2,934
754
2,231
4,851
3,096
5,888
2,135
2,332
0
0
0
0
0
0
4,612
119
4,047
1,831
2,871
5,328
5,860
7,493
10,946
13,000
14,670
14,525
15,900
15,968
16,976
47,253
52,156
51,135
54,298
61,355
81,346
74,694
80,623
87,186
83,775
83,444
93,884
110,908
106,606
107,057
104,839
105,828
100,750
117,290
109,066
120,345
115,063
124,745
117,822
110,462
122,282
121,395
144,472
175,738
186,083
148,949
164,959
180,751
214,158
215,894
215,280
230,250
238,338
251,891
261,365
318,394
363,566
384,343
342,633
393,429
377,150
402,970
377,404
396,384
381,215
411,712
448,351
396,097
424,419
374,937
373,399
430,147
466,507
419,622
461,316
597,913
610,222
572,498
633,704
637,163
691,232
777,547
660,535
739,177
739,177660,535777,547691,232637,163633,704572,498610,222597,913461,316419,622466,507430,147373,399374,937424,419396,097448,351411,712381,215396,384377,404402,970377,150393,429342,633384,343363,566318,394261,365251,891238,338230,250215,280215,894214,158180,751164,959148,949186,083175,738144,472121,395122,282110,462117,822124,745115,063120,345109,066117,290100,750105,828104,839107,057106,606110,90893,88483,44483,77587,18680,62374,69481,34661,35554,29851,13552,15647,25316,97615,96815,90014,52514,67013,00010,9467,4935,8605,3282,8711,8314,0471194,6120000002,3322,1355,8883,0964,8512,2317542,9342,9603,0185,0062,4664001,500900
       Inventory 
100
800
900
676
647
495
446
436
439
480
525
0
0
0
0
0
0
0
0
0
0
2,074
3,090
2,316
2,439
3,386
7,720
10,898
18,137
24,247
25,762
25,075
27,438
30,714
31,551
32,445
54,736
61,802
68,094
73,162
76,423
72,836
75,441
78,662
79,761
83,778
91,741
109,698
110,067
112,299
115,628
130,118
124,064
120,125
120,825
128,695
135,822
142,296
148,684
162,605
176,893
193,498
204,444
199,452
222,833
237,532
262,100
271,683
296,979
326,556
347,420
355,126
384,143
429,831
457,393
475,775
468,161
473,356
508,482
530,871
534,696
578,736
609,049
680,275
705,652
743,852
700,847
698,548
713,929
710,975
749,406
776,669
786,356
802,315
839,460
894,083
918,921
975,546
1,032,159
1,107,183
1,137,982
1,183,621
1,179,339
1,232,653
1,274,848
1,274,8481,232,6531,179,3391,183,6211,137,9821,107,1831,032,159975,546918,921894,083839,460802,315786,356776,669749,406710,975713,929698,548700,847743,852705,652680,275609,049578,736534,696530,871508,482473,356468,161475,775457,393429,831384,143355,126347,420326,556296,979271,683262,100237,532222,833199,452204,444193,498176,893162,605148,684142,296135,822128,695120,825120,125124,064130,118115,628112,299110,067109,69891,74183,77879,76178,66275,44172,83676,42373,16268,09461,80254,73632,44531,55130,71427,43825,07525,76224,24718,13710,8987,7203,3862,4392,3163,0902,0740000000000525480439436446495647676900800100
       Other Current Assets 
600
1,300
2,900
294
225
607
503
970
4,902
990
1,361
2,590
2,740
2,862
2,570
7,094
6,217
8,692
12,317
18,912
17,627
46,105
50,927
36,462
19,570
6,394
3,227
4,391
5,440
3,714
6,704
5,632
5,375
6,608
7,029
9,282
6,977
12,199
14,815
50,444
23,928
6,408
6,788
7,765
9,842
16,682
27,037
235
30,274
36,286
39,965
39,753
50,519
58,073
54,816
54,963
64,975
63,000
60,399
60,755
71,574
67,829
85,607
105,310
123,424
113,725
133,604
60,378
58,207
61,945
68,409
61,708
60,340
62,875
83,646
74,036
71,760
80,072
71,652
98,403
93,876
119,779
126,548
130,657
155,817
142,127
120,747
129,934
91,249
99,046
107,751
110,442
121,283
139,029
149,851
104,521
173,180
193,391
224,806
141,391
163,287
160,426
169,260
201,533
181,545
181,545201,533169,260160,426163,287141,391224,806193,391173,180104,521149,851139,029121,283110,442107,75199,04691,249129,934120,747142,127155,817130,657126,548119,77993,87698,40371,65280,07271,76074,03683,64662,87560,34061,70868,40961,94558,20760,378133,604113,725123,424105,31085,60767,82971,57460,75560,39963,00064,97554,96354,81658,07350,51939,75339,96536,28630,27423527,03716,6829,8427,7656,7886,40823,92850,44414,81512,1996,9779,2827,0296,6085,3755,6326,7043,7145,4404,3913,2276,39419,57036,46250,92746,10517,62718,91212,3178,6926,2177,0942,5702,8622,7402,5901,3619904,9029705036072252942,9001,300600
   > Long-term Assets 
21,300
30,300
36,100
37,127
32,938
32,558
31,910
32,392
29,582
34,735
39,760
35,028
33,880
36,418
36,099
29,544
28,322
31,333
30,240
31,071
30,471
165,829
171,543
147,689
127,334
127,911
126,654
126,362
109,470
123,907
127,706
129,212
129,119
140,707
149,822
170,982
143,974
152,741
162,025
168,999
186,708
337,456
349,090
449,436
465,774
463,608
690,344
758,363
760,316
766,281
808,052
833,879
783,695
850,993
847,990
858,181
875,269
880,600
907,051
1,111,799
1,094,318
1,125,458
1,362,614
1,064,824
2,135,958
2,434,760
2,449,264
2,639,729
2,674,203
1,981,358
2,175,667
2,601,899
2,585,819
2,561,145
2,530,668
2,425,981
2,355,607
2,344,612
2,287,401
2,370,913
2,518,543
2,586,616
2,698,769
2,747,896
2,606,592
2,654,544
3,419,111
3,505,801
3,516,287
3,540,659
3,665,905
3,728,940
3,668,683
3,628,243
3,581,339
3,623,617
3,591,590
3,613,055
3,802,855
3,885,515
3,887,661
3,807,491
3,794,605
3,756,513
3,679,102
3,679,1023,756,5133,794,6053,807,4913,887,6613,885,5153,802,8553,613,0553,591,5903,623,6173,581,3393,628,2433,668,6833,728,9403,665,9053,540,6593,516,2873,505,8013,419,1112,654,5442,606,5922,747,8962,698,7692,586,6162,518,5432,370,9132,287,4012,344,6122,355,6072,425,9812,530,6682,561,1452,585,8192,601,8992,175,6671,981,3582,674,2032,639,7292,449,2642,434,7602,135,9581,064,8241,362,6141,125,4581,094,3181,111,799907,051880,600875,269858,181847,990850,993783,695833,879808,052766,281760,316758,363690,344463,608465,774449,436349,090337,456186,708168,999162,025152,741143,974170,982149,822140,707129,119129,212127,706123,907109,470126,362126,654127,911127,334147,689171,543165,82930,47131,07130,24031,33328,32229,54436,09936,41833,88035,02839,76034,73529,58232,39231,91032,55832,93837,12736,10030,30021,300
       Property Plant Equipment 
8,600
17,000
22,900
25,093
20,743
20,387
20,031
20,715
19,983
22,921
27,996
32,560
33,059
32,704
30,994
28,206
26,338
24,900
23,993
25,154
24,447
27,000
35,620
42,501
41,179
39,556
37,799
37,321
36,251
51,615
52,469
55,466
56,487
58,780
66,249
76,818
95,732
105,199
110,716
124,979
142,252
159,789
182,099
199,141
203,949
212,620
213,755
221,866
217,884
216,496
266,190
268,971
264,317
267,374
273,724
284,473
281,865
282,002
285,664
319,316
437,066
469,862
486,741
523,516
538,117
568,051
604,513
704,207
716,916
724,494
729,836
798,768
824,013
851,097
878,624
896,700
895,392
900,480
924,033
948,682
951,890
962,970
969,300
1,010,868
1,009,972
1,010,917
1,015,062
1,032,471
1,022,474
1,026,579
1,024,787
1,035,461
1,039,544
1,049,464
1,051,821
1,073,366
1,068,142
1,067,278
1,067,156
1,066,133
1,060,425
1,052,898
1,045,408
1,043,041
1,032,613
1,032,6131,043,0411,045,4081,052,8981,060,4251,066,1331,067,1561,067,2781,068,1421,073,3661,051,8211,049,4641,039,5441,035,4611,024,7871,026,5791,022,4741,032,4711,015,0621,010,9171,009,9721,010,868969,300962,970951,890948,682924,033900,480895,392896,700878,624851,097824,013798,768729,836724,494716,916704,207604,513568,051538,117523,516486,741469,862437,066319,316285,664282,002281,865284,473273,724267,374264,317268,971266,190216,496217,884221,866213,755212,620203,949199,141182,099159,789142,252124,979110,716105,19995,73276,81866,24958,78056,48755,46652,46951,61536,25137,32137,79939,55641,17942,50135,62027,00024,44725,15423,99324,90026,33828,20630,99432,70433,05932,56027,99622,92119,98320,71520,03120,38720,74325,09322,90017,0008,600
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,250
45,053
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
23,722
40,360
40,360
53,364
53,364
53,055
53,055
51,543
51,543
51,543
51,543
51,543
51,543
54,975
54,975
54,258
54,258
54,258
54,258
54,258
54,258
202,392
202,392
202,392
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039197,039202,392202,392202,39254,25854,25854,25854,25854,25854,25854,97554,97551,54351,54351,54351,54351,54351,54353,05553,05553,36453,36440,36040,36023,72221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26221,26245,05332,2500000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
118,085
90,116
129,253
142,511
154,327
146,808
94,944
55,833
123,155
107,589
117,073
124,498
124,906
148,625
268,516
251,928
244,588
449,143
98,895
224,810
509,627
514,381
443,708
314,404
201,620
362,956
572,711
533,628
482,036
416,304
385,785
313,599
279,988
204,883
235,864
320,000
374,965
431,804
411,978
290,796
323,058
265,122
285,473
321,127
350,237
466,618
507,793
462,827
412,503
372,302
333,835
340,635
385,777
548,002
611,135
620,551
557,083
561,985
521,238
506,724
506,724521,238561,985557,083620,551611,135548,002385,777340,635333,835372,302412,503462,827507,793466,618350,237321,127285,473265,122323,058290,796411,978431,804374,965320,000235,864204,883279,988313,599385,785416,304482,036533,628572,711362,956201,620314,404443,708514,381509,627224,81098,895449,143244,588251,928268,516148,625124,906124,498117,073107,589123,15555,83394,944146,808154,327142,511129,25390,116118,085000000000000000000000000000000000000000000000
       Intangible Assets 
11,400
11,900
11,600
11,462
11,159
10,856
10,345
9,862
9,333
8,868
8,314
0
0
0
0
0
0
0
0
0
0
133,090
131,373
61,504
37,427
37,140
36,854
36,558
14,934
13,841
12,748
11,655
10,563
9,470
8,377
9,596
8,420
7,244
6,068
7,626
6,316
4,391
4,194
40,977
77,416
77,985
104,604
103,648
102,692
101,736
100,780
180,277
170,914
168,267
165,624
162,980
172,016
168,434
165,791
163,147
165,397
163,045
159,949
156,578
926,896
923,861
920,943
683,996
1,177,232
568,966
561,387
553,780
546,172
538,565
530,957
517,510
509,902
502,295
494,687
491,808
485,981
476,632
462,849
456,580
443,717
433,381
427,172
417,271
405,903
394,298
388,487
388,652
374,251
369,368
354,024
338,569
325,989
310,343
302,476
294,701
279,653
265,533
260,920
255,278
247,346
247,346255,278260,920265,533279,653294,701302,476310,343325,989338,569354,024369,368374,251388,652388,487394,298405,903417,271427,172433,381443,717456,580462,849476,632485,981491,808494,687502,295509,902517,510530,957538,565546,172553,780561,387568,9661,177,232683,996920,943923,861926,896156,578159,949163,045165,397163,147165,791168,434172,016162,980165,624168,267170,914180,277100,780101,736102,692103,648104,60477,98577,41640,9774,1944,3916,3167,6266,0687,2448,4209,5968,3779,47010,56311,65512,74813,84114,93436,55836,85437,14037,42761,504131,373133,09000000000008,3148,8689,3339,86210,34510,85611,15911,46211,60011,90011,400
       Long-term Assets Other 
1,300
1,400
1,600
572
1,036
1,315
1,534
1,815
266
2,946
3,450
2,468
821
3,714
5,105
1,338
1,984
6,433
6,247
5,917
6,024
5,739
4,550
43,684
48,728
51,215
52,001
52,483
37,023
37,189
41,227
40,829
40,807
51,195
53,934
63,306
18,560
19,036
23,979
12,584
12,500
12,689
12,578
15,306
14,112
14,558
12,413
14,215
12,227
12,267
13,559
15,495
19,849
20,061
19,739
16,611
15,158
14,883
14,010
143,171
41,545
46,562
61,532
65,281
80,332
58,284
60,790
408,644
25,400
23,057
36,443
32,815
26,580
21,447
22,985
29,852
32,666
39,430
37,565
36,568
96,300
99,456
112,646
122,009
125,918
135,852
119,009
142,237
141,198
141,663
144,705
151,760
149,186
151,797
151,788
176,236
150,057
144,168
165,069
171,538
184,790
180,117
199,314
251,391
235,654
235,654251,391199,314180,117184,790171,538165,069144,168150,057176,236151,788151,797149,186151,760144,705141,663141,198142,237119,009135,852125,918122,009112,64699,45696,30036,56837,56539,43032,66629,85222,98521,44726,58032,81536,44323,05725,400408,64460,79058,28480,33265,28161,53246,56241,545143,17114,01014,88315,15816,61119,73920,06119,84915,49513,55912,26712,22714,21512,41314,55814,11215,30612,57812,68912,50012,58423,97919,03618,56063,30653,93451,19540,80740,82941,22737,18937,02352,48352,00151,21548,72843,6844,5505,7396,0245,9176,2476,4331,9841,3385,1053,7148212,4683,4502,9462661,8151,5341,3151,0365721,6001,4001,300
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,017
231,947
228,400
229,172
222,649
221,239
220,593
229,771
225,501
226,757
235,400
238,703
150,391
144,124
147,143
150,991
166,296
163,411
172,545
146,245
220,191
243,212
266,182
288,006
446,786
458,387
470,961
484,759
399,095
407,009
425,380
429,194
460,952
467,333
475,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000475,554467,333460,952429,194425,380407,009399,095484,759470,961458,387446,786288,006266,182243,212220,191146,245172,545163,411166,296150,991147,143144,124150,391238,703235,400226,757225,501229,771220,593221,239222,649229,172228,400231,947236,01700000000000000000000000000000000000000000000000
> Total Liabilities 
1,700
34,000
5,700
5,172
4,759
2,894
3,672
6,939
3,684
5,321
6,236
12,263
12,938
11,194
11,259
12,073
17,215
143,948
142,483
138,487
140,524
304,226
298,067
300,944
271,168
277,689
274,221
272,765
442,224
419,827
344,955
345,634
285,050
614,037
616,511
627,553
618,536
628,528
621,137
630,020
626,343
561,003
565,504
594,978
620,965
622,554
658,869
545,366
543,306
548,087
520,537
530,633
525,135
532,101
552,182
585,880
348,141
343,262
344,044
908,176
880,607
883,716
931,991
962,559
1,233,231
1,291,732
1,332,213
1,328,521
1,376,757
1,169,728
1,196,430
1,257,415
1,169,520
1,224,386
1,767,135
1,824,462
1,789,714
1,739,575
1,780,309
1,459,188
1,498,771
1,432,430
1,483,723
1,567,658
1,482,879
2,065,431
2,104,197
1,742,018
1,643,043
1,656,925
1,711,326
1,732,585
1,671,392
1,641,034
1,695,526
1,771,918
1,774,652
1,780,345
1,861,266
1,890,054
1,798,857
1,780,822
1,437,799
1,330,950
1,353,548
1,353,5481,330,9501,437,7991,780,8221,798,8571,890,0541,861,2661,780,3451,774,6521,771,9181,695,5261,641,0341,671,3921,732,5851,711,3261,656,9251,643,0431,742,0182,104,1972,065,4311,482,8791,567,6581,483,7231,432,4301,498,7711,459,1881,780,3091,739,5751,789,7141,824,4621,767,1351,224,3861,169,5201,257,4151,196,4301,169,7281,376,7571,328,5211,332,2131,291,7321,233,231962,559931,991883,716880,607908,176344,044343,262348,141585,880552,182532,101525,135530,633520,537548,087543,306545,366658,869622,554620,965594,978565,504561,003626,343630,020621,137628,528618,536627,553616,511614,037285,050345,634344,955419,827442,224272,765274,221277,689271,168300,944298,067304,226140,524138,487142,483143,94817,21512,07311,25911,19412,93812,2636,2365,3213,6846,9393,6722,8944,7595,1725,70034,0001,700
   > Total Current Liabilities 
1,600
7,900
5,600
5,087
4,682
2,826
3,609
6,883
3,637
5,123
6,090
8,302
9,435
7,731
8,347
6,847
12,719
15,251
16,243
12,815
15,161
81,270
75,715
70,054
50,695
43,702
44,224
40,367
56,887
38,004
43,229
46,045
38,829
44,543
49,062
61,543
53,311
63,423
120,735
130,081
126,314
60,033
64,070
78,154
78,699
83,930
92,097
83,844
75,986
82,035
83,254
94,125
119,814
119,997
134,929
170,433
144,008
142,241
167,633
183,271
156,038
166,720
206,550
235,739
305,506
347,704
390,491
445,457
388,011
364,580
377,335
439,310
340,206
374,303
417,529
816,518
773,471
804,950
838,660
523,241
500,986
439,428
493,745
932,503
820,470
813,302
854,693
492,548
430,035
443,344
514,898
539,822
490,418
464,727
521,020
588,884
598,231
597,231
1,163,223
117,702
1,087,900
1,067,337
715,658
606,988
628,213
628,213606,988715,6581,067,3371,087,900117,7021,163,223597,231598,231588,884521,020464,727490,418539,822514,898443,344430,035492,548854,693813,302820,470932,503493,745439,428500,986523,241838,660804,950773,471816,518417,529374,303340,206439,310377,335364,580388,011445,457390,491347,704305,506235,739206,550166,720156,038183,271167,633142,241144,008170,433134,929119,997119,81494,12583,25482,03575,98683,84492,09783,93078,69978,15464,07060,033126,314130,081120,73563,42353,31161,54349,06244,54338,82946,04543,22938,00456,88740,36744,22443,70250,69570,05475,71581,27015,16112,81516,24315,25112,7196,8478,3477,7319,4358,3026,0905,1233,6376,8833,6092,8264,6825,0875,6007,9001,600
       Short-term Debt 
0
0
0
26
26
29
28
27
29
98
95
1,591
1,718
0
0
0
0
0
0
118,396
0
58,228
48,747
42,805
25,056
12,145
11,696
11,337
27,048
6,705
6,787
6,787
6,786
6,785
6,549
6,309
6,065
5,816
45,193
141,482
70,317
0
0
0
0
0
0
75,620
0
0
0
0
23,455
23,440
23,440
23,365
0
0
0
0
0
0
0
642,902
0
0
0
662,286
0
24,420
22,460
22,478
22,495
676,205
17,430
360,949
365,326
369,752
374,230
0
9,210
10,165
10,225
372,582
376,365
381,487
385,220
11,754
11,227
11,024
9,659
10,464
10,829
10,611
9,226
10,375
9,251
8,294
502,722
502,656
502,931
505,526
15,551
7,574
0
07,57415,551505,526502,931502,656502,7228,2949,25110,3759,22610,61110,82910,4649,65911,02411,22711,754385,220381,487376,365372,58210,22510,1659,2100374,230369,752365,326360,94917,430676,20522,49522,47822,46024,4200662,286000642,902000000023,36523,44023,44023,455000075,62000000070,317141,48245,1935,8166,0656,3096,5496,7856,7866,7876,7876,70527,04811,33711,69612,14525,05642,80548,74758,2280118,3960000001,7181,5919598292728292626000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
642,902
0
0
0
662,286
0
72,238
71,206
22,478
67,759
676,205
1,166,036
360,949
365,326
369,752
374,230
0
6,347
0
0
361,882
365,964
370,100
374,290
0
0
0
0
0
0
0
0
0
0
0
493,398
493,877
494,357
494,837
0
0
0
000494,837494,357493,877493,39800000000000374,290370,100365,964361,882006,3470374,230369,752365,326360,9491,166,036676,20567,75922,47871,20672,2380662,286000642,902000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
800
6,000
5,000
3,095
1,367
990
1,792
4,747
1,616
3,049
3,923
4,284
3,188
2,014
763
3,930
9,532
12,123
13,399
10,098
2,299
840
466
27,249
2,470
2,324
539
484
440
231
1,498
2,285
748
754
1,313
1,169
2,326
2,847
2,029
58,851
5,178
31,012
2,076
7,567
3,276
9,708
7,184
4,956
5,274
7,252
7,107
36,088
12,439
12,501
11,459
67,149
69,808
68,358
74,298
95,302
79,723
101,050
115,752
235,739
130,068
135,768
162,926
392,511
152,860
153,651
148,773
191,353
135,604
158,229
364,920
166,616
172,192
166,416
177,396
207,620
412,830
429,502
483,745
240,981
235,163
205,870
218,021
191,429
399,225
411,132
203,321
193,003
187,810
199,251
207,165
231,238
264,778
277,944
301,369
315,509
292,238
257,412
312,321
235,403
293,751
293,751235,403312,321257,412292,238315,509301,369277,944264,778231,238207,165199,251187,810193,003203,321411,132399,225191,429218,021205,870235,163240,981483,745429,502412,830207,620177,396166,416172,192166,616364,920158,229135,604191,353148,773153,651152,860392,511162,926135,768130,068235,739115,752101,05079,72395,30274,29868,35869,80867,14911,45912,50112,43936,0887,1077,2525,2744,9567,1849,7083,2767,5672,07631,0125,17858,8512,0292,8472,3261,1691,3137547482,2851,4982314404845392,3242,47027,2494668402,29910,09813,39912,1239,5323,9307632,0143,1884,2843,9233,0491,6164,7471,7929901,3673,0955,0006,000800
       Other Current Liabilities 
800
1,900
600
1,966
3,289
1,807
1,789
2,109
1,992
1,976
2,072
2,427
4,529
5,717
7,584
2,917
3,187
3,128
2,844
2,717
12,862
22,202
26,502
42,805
23,169
19,391
22,397
20,450
19,506
22,842
27,702
29,881
24,141
29,850
34,561
48,738
40,041
51,524
117,263
-141,300
50,699
28,092
61,845
70,501
75,265
74,222
84,913
3,056
66,999
70,595
72,310
54,159
79,627
82,614
97,470
77,847
72,195
69,926
89,095
84,366
72,811
62,934
86,093
98,991
169,708
205,578
221,525
52,946
223,121
177,194
198,141
217,631
173,929
216,074
52,609
273,685
225,732
256,933
278,422
307,836
88,156
9,926
10,000
297,508
192,609
213,001
240,990
289,213
30,810
32,212
48,187
329,399
283,030
254,560
304,214
330,347
324,202
597,231
347,859
351,588
281,509
283,623
371,891
357,649
628,213
628,213357,649371,891283,623281,509351,588347,859597,231324,202330,347304,214254,560283,030329,39948,18732,21230,810289,213240,990213,001192,609297,50810,0009,92688,156307,836278,422256,933225,732273,68552,609216,074173,929217,631198,141177,194223,12152,946221,525205,578169,70898,99186,09362,93472,81184,36689,09569,92672,19577,84797,47082,61479,62754,15972,31070,59566,9993,05684,91374,22275,26570,50161,84528,09250,699-141,300117,26351,52440,04148,73834,56129,85024,14129,88127,70222,84219,50620,45022,39719,39123,16942,80526,50222,20212,8622,7172,8443,1283,1872,9177,5845,7174,5292,4272,0721,9761,9922,1091,7891,8073,2891,9666001,900800
   > Long-term Liabilities 
100
26,100
100
85
77
68
63
56
47
198
146
3,961
3,503
3,463
2,912
5,226
4,496
128,697
126,240
125,672
125,363
222,956
222,352
230,890
220,473
233,987
229,997
232,398
385,337
381,823
301,726
299,589
246,221
569,494
567,449
566,010
565,225
565,105
500,402
499,939
500,029
500,970
501,434
516,824
542,266
538,624
566,772
461,522
467,320
466,052
437,283
436,508
405,321
412,104
417,253
415,447
204,133
201,021
176,411
724,905
724,569
716,996
725,441
726,820
927,725
944,028
941,722
883,064
988,746
805,148
819,095
818,105
829,314
850,083
1,349,606
1,007,944
1,016,243
934,625
941,649
935,947
997,785
993,002
989,978
635,155
662,409
1,252,129
1,249,504
1,249,470
1,213,008
1,213,581
1,196,428
1,192,763
1,180,974
1,176,307
1,174,506
1,183,034
1,176,421
1,183,114
698,043
713,030
710,957
713,485
722,141
723,962
725,335
725,335723,962722,141713,485710,957713,030698,0431,183,1141,176,4211,183,0341,174,5061,176,3071,180,9741,192,7631,196,4281,213,5811,213,0081,249,4701,249,5041,252,129662,409635,155989,978993,002997,785935,947941,649934,6251,016,2431,007,9441,349,606850,083829,314818,105819,095805,148988,746883,064941,722944,028927,725726,820725,441716,996724,569724,905176,411201,021204,133415,447417,253412,104405,321436,508437,283466,052467,320461,522566,772538,624542,266516,824501,434500,970500,029499,939500,402565,105565,225566,010567,449569,494246,221299,589301,726381,823385,337232,398229,997233,987220,473230,890222,352222,956125,363125,672126,240128,6974,4965,2262,9123,4633,5033,96114619847566368778510026,100100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
497,083
497,083
377,521
377,521
377,520
348,339
348,329
324,872
324,865
324,861
324,859
109,849
109,822
78,310
655,566
661,419
650,872
656,884
657,976
655,491
661,492
667,793
662,286
668,009
645,685
653,178
660,761
668,437
676,205
1,166,036
813,521
817,672
821,871
826,119
830,417
834,766
839,165
853,160
486,238
486,713
1,073,202
1,074,164
1,075,145
1,076,127
1,077,110
1,078,093
1,079,077
1,080,061
1,081,047
1,082,033
0
1,084,006
1,084,994
0
0
0
0
0
0
0
00000001,084,9941,084,00601,082,0331,081,0471,080,0611,079,0771,078,0931,077,1101,076,1271,075,1451,074,1641,073,202486,713486,238853,160839,165834,766830,417826,119821,871817,672813,5211,166,036676,205668,437660,761653,178645,685668,009662,286667,793661,492655,491657,976656,884650,872661,419655,56678,310109,822109,849324,859324,861324,865324,872348,329348,339377,520377,521377,521497,083497,083000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,017
231,947
228,400
229,172
222,649
221,239
220,593
229,771
225,501
226,757
235,400
238,703
150,391
144,124
147,143
150,991
166,296
163,411
172,545
146,245
220,191
243,212
266,182
288,006
446,786
458,387
470,961
484,759
399,095
407,009
425,380
429,194
460,952
467,333
475,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000475,554467,333460,952429,194425,380407,009399,095484,759470,961458,387446,786288,006266,182243,212220,191146,245172,545163,411166,296150,991147,143144,124150,391238,703235,400226,757225,501229,771220,593221,239222,649229,172228,400231,947236,01700000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,843
1,816
3,697
1,240
0
363
704
290
2,852
3,049
18,022
15,550
19,476
17,501
14,512
8,642
7,101
5,776
4,787
3,128
2,082
1,769
1,917
3,162
2,586
2,724
3,708
4,218
17,196
28,700
25,100
42,552
47,484
53,282
52,015
52,427
53,052
47,751
54,541
59,694
57,292
56,763
54,017
60,911
69,339
63,150
66,124
68,557
68,844
79,032
89,334
80,727
77,251
177,210
159,463
165,917
157,344
160,877
173,878
183,570
194,423
198,571
112,754
115,530
105,530
115,068
99,958
91,319
98,117
175,696
132,099
129,939
174,325
136,881
136,471
118,335
113,686
100,913
95,260
92,473
73,502
92,415
0
105,457
0
0
0
0
0
0
000000105,457092,41573,50292,47395,260100,913113,686118,335136,471136,881174,325129,939132,099175,69698,11791,31999,958115,068105,530115,530112,754198,571194,423183,570173,878160,877157,344165,917159,463177,21077,25180,72789,33479,03268,84468,55766,12463,15069,33960,91154,01756,76357,29259,69454,54147,75153,05252,42752,01553,28247,48442,55225,10028,70017,1964,2183,7082,7242,5863,1621,9171,7692,0823,1284,7875,7767,1018,64214,51217,50119,47615,55018,0223,0492,85229070436301,2403,6971,8161,843000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,296
37,521
37,182
37,190
0
0
0
0
0
193,202
193,202
193,202
143,527
143,527
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000143,527143,527193,202193,202193,2020000037,19037,18237,52133,2960000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
25,100
17,400
106,800
98,377
89,731
83,196
79,652
69,994
61,759
93,000
84,166
159,548
144,368
130,779
116,210
98,543
165,902
162,437
141,963
117,853
98,772
43,190
14,163
-67,978
-90,235
-110,442
-65,379
-77,462
46,005
48,887
122,117
117,802
164,714
167,602
174,545
187,726
209,166
226,027
237,901
276,675
273,940
283,434
303,853
322,185
345,240
362,962
585,664
717,257
720,840
732,305
774,539
773,048
771,950
1,000,426
1,015,194
1,015,763
1,250,152
1,258,258
1,276,486
1,341,041
1,460,121
1,461,969
1,508,442
1,527,894
2,425,455
2,356,957
2,292,640
2,400,847
2,290,236
1,917,576
2,645,808
2,766,275
2,769,087
2,795,579
2,813,562
2,808,663
2,807,003
2,885,104
2,914,945
2,967,940
2,936,627
2,960,954
3,074,405
3,122,381
3,239,962
3,236,679
4,053,893
4,106,002
4,162,010
4,241,571
4,266,149
4,270,740
4,391,315
4,504,807
4,568,514
4,603,156
4,659,043
4,782,827
4,896,897
4,951,549
5,073,816
5,286,299
5,413,396
5,657,990
5,793,459
5,793,4595,657,9905,413,3965,286,2995,073,8164,951,5494,896,8974,782,8274,659,0434,603,1564,568,5144,504,8074,391,3154,270,7404,266,1494,241,5714,162,0104,106,0024,053,8933,236,6793,239,9623,122,3813,074,4052,960,9542,936,6272,967,9402,914,9452,885,1042,807,0032,808,6632,813,5622,795,5792,769,0872,766,2752,645,8081,917,5762,290,2362,400,8472,292,6402,356,9572,425,4551,527,8941,508,4421,461,9691,460,1211,341,0411,276,4861,258,2581,250,1521,015,7631,015,1941,000,426771,950773,048774,539732,305720,840717,257585,664362,962345,240322,185303,853283,434273,940276,675237,901226,027209,166187,726174,545167,602164,714117,802122,11748,88746,005-77,462-65,379-110,442-90,235-67,97814,16343,19098,772117,853141,963162,437165,90298,543116,210130,779144,368159,54884,16693,00061,75969,99479,65283,19689,73198,377106,80017,40025,100
   Common Stock
0
0
0
35
35
35
37
37
37
42
42
52
53
53
54
54
63
64
64
64
64
64
64
65
65
65
74
75
85
85
91
92
96
96
97
97
98
99
100
100
100
100
101
101
102
102
103
111
111
112
114
115
116
123
124
126
139
140
142
144
146
147
148
149
161
161
162
162
163
164
173
173
173
175
176
176
177
178
178
178
179
179
180
180
181
181
181
182
183
183
184
184
185
186
186
186
188
188
188
189
190
190
191
191
0
01911911901901891881881881861861861851841841831831821811811811801801791791781781781771761761751731731731641631621621611611491481471461441421401391261241231161151141121111111031021021011011001001001009998979796969291858575746565656464646464646354545353524242373737353535000
   Retained Earnings -9,009-194,695-319,638-425,718-532,892-621,554-641,929-682,307-738,347-789,199-788,949-777,227-804,891-925,689-867,791-831,297-844,238-861,609-883,708-1,668,511-1,639,328-1,720,709-1,735,733-1,790,769-1,753,334-1,694,134-1,690,475-1,677,855-1,661,063-1,637,548-1,586,156-1,573,629-1,536,796-1,520,506-1,573,068-1,530,271-1,106,711-1,021,569-1,090,186-999,260-917,271-849,770-779,973-787,418-753,916-715,801-653,811-600,791-579,258-539,448-486,436-481,079-449,073-425,101-398,366-380,713-375,636-371,265-359,076-576,410-575,933-577,084-581,795-588,436-589,748-576,596-601,102-601,931-605,741-607,427-609,997-604,781-600,917-591,624-581,233-574,197-572,871-563,091-548,095-532,619-511,279-488,821-406,399-376,921-321,323-301,378-275,651-254,360-245,263-225,580-206,250-189,133-174,722-148,119-113,197-102,182-90,213-80,513-70,119-61,970-54,884-43,149-34,100-26,500-19,600
   Accumulated Other Comprehensive Income 
-6,000
-5,800
-5,400
-5,101
-4,832
-4,510
-3,422
-3,470
-3,285
2,033
2,217
-14,248
2,568
3,046
3,996
5,031
5,043
5,128
5,195
5,057
5,102
-530
-260
-363
-235
-144
-16
-16
-15
-49
-24
-25
-5
-7
128
139
351
-575
-2,754
1,106
2,069
101
-704
933
4,405
10,224
-1,581
188
-5,787
-5,923
1,304
4,887
2,512
4,650
2,333
-202
1,155
2,441
11,473
5,018
7,275
9,941
19,189
27,466
43,819
32,461
25,184
21,033
47
4,528
2,158
12,816
5,020
-14,658
-21,434
-22,961
-28,545
-1,129
-2,160
5,271
19,794
17,439
37,003
20,164
34,127
30,050
10,385
-16,139
5,004
-939
10,239
14,432
-877
18,472
30,749
-3,867
-10,722
-18,617
6,257
-28,788
-12,746
15,126
4,650
61,653
19,151
19,15161,6534,65015,126-12,746-28,7886,257-18,617-10,722-3,86730,74918,472-87714,43210,239-9395,004-16,13910,38530,05034,12720,16437,00317,43919,7945,271-2,160-1,129-28,545-22,961-21,434-14,6585,02012,8162,1584,5284721,03325,18432,46143,81927,46619,1899,9417,2755,01811,4732,4411,155-2022,3334,6502,5124,8871,304-5,923-5,787188-1,58110,2244,405933-7041012,0691,106-2,754-575351139128-7-5-25-24-49-15-16-16-144-235-363-260-5305,1025,0575,1955,1285,0435,0313,9963,0462,568-14,2482,2172,033-3,285-3,470-3,422-4,510-4,832-5,101-5,400-5,800-6,000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
931,361
948,394
1,090,188
1,103,885
1,122,732
1,175,422
1,197,082
1,221,933
1,483,336
1,505,776
1,561,890
1,833,831
1,863,961
1,926,133
2,059,101
2,213,347
2,249,445
2,278,761
2,359,744
3,308,137
3,337,503
3,371,377
3,414,837
3,410,297
3,458,124
4,231,514
4,288,113
4,314,793
4,397,980
4,435,449
4,483,220
4,510,451
4,577,300
4,620,817
4,669,926
4,682,900
4,744,316
4,782,916
4,832,707
4,854,814
4,885,637
4,937,791
4,993,407
5,010,619
5,083,831
5,133,742
5,191,502
5,206,287
5,272,666
5,335,853
0
5,417,873
5,493,956
0
0
0
0
0
0
0
00000005,493,9565,417,87305,335,8535,272,6665,206,2875,191,5025,133,7425,083,8315,010,6194,993,4074,937,7914,885,6374,854,8144,832,7074,782,9164,744,3164,682,9004,669,9264,620,8174,577,3004,510,4514,483,2204,435,4494,397,9804,314,7934,288,1134,231,5143,458,1243,410,2973,414,8373,371,3773,337,5033,308,1372,359,7442,278,7612,249,4452,213,3472,059,1011,926,1331,863,9611,833,8311,561,8901,505,7761,483,3361,221,9331,197,0821,175,4221,122,7321,103,8851,090,188948,394931,361000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
50,700
49,700
146,300
146,592
149,412
149,641
153,156
153,940
155,220
193,107
195,104
0
316,469
316,813
318,410
319,038
406,059
411,605
412,355
414,110
414,929
420,577
420,758
421,206
421,214
422,256
482,658
485,570
618,806
623,048
703,283
709,359
765,540
772,294
784,317
794,917
814,458
828,434
841,657
852,065
861,519
871,669
886,251
898,235
916,666
929,046
946,218
1,088,223
1,102,152
1,118,829
1,171,487
1,193,147
1,218,395
1,476,732
1,499,173
1,555,287
1,828,116
1,856,468
1,918,682
2,051,680
2,206,616
2,239,299
2,269,078
2,350,049
3,298,746
3,323,595
3,357,480
3,401,221
3,396,737
3,443,155
4,216,545
4,273,792
4,300,690
4,383,691
4,420,976
4,468,996
4,496,434
4,563,910
4,607,402
4,656,625
4,669,988
4,734,105
4,772,955
4,822,746
4,844,982
4,874,959
4,927,035
4,983,568
5,001,061
5,073,624
5,123,517
5,181,813
5,196,898
5,263,376
5,326,528
5,396,036
5,407,924
5,483,563
5,532,381
5,601,702
5,607,564
5,696,701
5,728,193
5,790,841
5,783,317
5,783,3175,790,8415,728,1935,696,7015,607,5645,601,7025,532,3815,483,5635,407,9245,396,0365,326,5285,263,3765,196,8985,181,8135,123,5175,073,6245,001,0614,983,5684,927,0354,874,9594,844,9824,822,7464,772,9554,734,1054,669,9884,656,6254,607,4024,563,9104,496,4344,468,9964,420,9764,383,6914,300,6904,273,7924,216,5453,443,1553,396,7373,401,2213,357,4803,323,5953,298,7462,350,0492,269,0782,239,2992,206,6162,051,6801,918,6821,856,4681,828,1161,555,2871,499,1731,476,7321,218,3951,193,1471,171,4871,118,8291,102,1521,088,223946,218929,046916,666898,235886,251871,669861,519852,065841,657828,434814,458794,917784,317772,294765,540709,359703,283623,048618,806485,570482,658422,256421,214421,206420,758420,577414,929414,110412,355411,605406,059319,038318,410316,813316,4690195,104193,107155,220153,940153,156149,641149,412146,592146,30049,70050,700



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,853,915
Cost of Revenue-580,235
Gross Profit2,273,6802,273,680
 
Operating Income (+$)
Gross Profit2,273,680
Operating Expense-1,789,466
Operating Income484,214484,214
 
Operating Expense (+$)
Research Development747,184
Selling General Administrative532,300
Selling And Marketing Expenses476,700
Operating Expense1,789,4661,756,184
 
Net Interest Income (+$)
Interest Income74,883
Interest Expense-12,666
Other Finance Cost-64
Net Interest Income62,153
 
Pretax Income (+$)
Operating Income484,214
Net Interest Income62,153
Other Non-Operating Income Expenses0
Income Before Tax (EBT)541,763426,665
EBIT - interestExpense = 541,763
541,763
439,525
Interest Expense12,666
Earnings Before Interest and Taxes (EBIT)554,429554,429
Earnings Before Interest and Taxes (EBITDA)650,855
 
After tax Income (+$)
Income Before Tax541,763
Tax Provision-114,904
Net Income From Continuing Ops426,859426,859
Net Income426,859
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,369,701
Total Other Income/Expenses Net57,549-62,153
 

Technical Analysis of Biomarin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biomarin. The general trend of Biomarin is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biomarin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Biomarin Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biomarin Pharmaceutical Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 58.17 < 65.40 < 68.42.

The bearish price targets are: 53.72 > 53.72 > 52.93.

Know someone who trades $BMRN? Share this with them.👇

Biomarin Pharmaceutical Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biomarin Pharmaceutical Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biomarin Pharmaceutical Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biomarin Pharmaceutical Inc. The current macd is -0.56040123.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biomarin price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biomarin. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biomarin price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Biomarin Pharmaceutical Inc Daily Moving Average Convergence/Divergence (MACD) ChartBiomarin Pharmaceutical Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biomarin Pharmaceutical Inc. The current adx is 15.17.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biomarin shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Biomarin Pharmaceutical Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biomarin Pharmaceutical Inc. The current sar is 53.93.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Biomarin Pharmaceutical Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biomarin Pharmaceutical Inc. The current rsi is 55.64. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Biomarin Pharmaceutical Inc Daily Relative Strength Index (RSI) ChartBiomarin Pharmaceutical Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biomarin Pharmaceutical Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biomarin price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Biomarin Pharmaceutical Inc Daily Stochastic Oscillator ChartBiomarin Pharmaceutical Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biomarin Pharmaceutical Inc. The current cci is 112.08.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Biomarin Pharmaceutical Inc Daily Commodity Channel Index (CCI) ChartBiomarin Pharmaceutical Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biomarin Pharmaceutical Inc. The current cmo is 29.45.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Biomarin Pharmaceutical Inc Daily Chande Momentum Oscillator (CMO) ChartBiomarin Pharmaceutical Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biomarin Pharmaceutical Inc. The current willr is -13.08840413.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Biomarin Pharmaceutical Inc Daily Williams %R ChartBiomarin Pharmaceutical Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biomarin Pharmaceutical Inc. The current atr is 1.42438608.

Biomarin Pharmaceutical Inc Daily Average True Range (ATR) ChartBiomarin Pharmaceutical Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biomarin Pharmaceutical Inc. The current obv is 9,643,505.

Biomarin Pharmaceutical Inc Daily On-Balance Volume (OBV) ChartBiomarin Pharmaceutical Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biomarin Pharmaceutical Inc. The current mfi is 53.28.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Biomarin Pharmaceutical Inc Daily Money Flow Index (MFI) ChartBiomarin Pharmaceutical Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biomarin Pharmaceutical Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Biomarin Pharmaceutical Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biomarin Pharmaceutical Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.644
Ma 20Greater thanMa 5055.822
Ma 50Greater thanMa 10058.247
Ma 100Greater thanMa 20062.571
OpenGreater thanClose57.460
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Biomarin with someone you think should read this too:
  • Are you bullish or bearish on Biomarin? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biomarin? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biomarin Pharmaceutical Inc

I send you an email if I find something interesting about Biomarin Pharmaceutical Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Biomarin Pharmaceutical Inc.

Receive notifications about Biomarin Pharmaceutical Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.